<code id='B197FBDBA1'></code><style id='B197FBDBA1'></style>
    • <acronym id='B197FBDBA1'></acronym>
      <center id='B197FBDBA1'><center id='B197FBDBA1'><tfoot id='B197FBDBA1'></tfoot></center><abbr id='B197FBDBA1'><dir id='B197FBDBA1'><tfoot id='B197FBDBA1'></tfoot><noframes id='B197FBDBA1'>

    • <optgroup id='B197FBDBA1'><strike id='B197FBDBA1'><sup id='B197FBDBA1'></sup></strike><code id='B197FBDBA1'></code></optgroup>
        1. <b id='B197FBDBA1'><label id='B197FBDBA1'><select id='B197FBDBA1'><dt id='B197FBDBA1'><span id='B197FBDBA1'></span></dt></select></label></b><u id='B197FBDBA1'></u>
          <i id='B197FBDBA1'><strike id='B197FBDBA1'><tt id='B197FBDBA1'><pre id='B197FBDBA1'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:494
          Garry Tan, CEO of Y Combinator Seb Daly/Web Summi

          WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of the startup economy’s most recognizable figures. Well before he became the leader of the coveted startup accelerator that bred global brands like Airbnb, Stripe and OpenAI, Tan was a self-made founder who sold his own company to Twitter.

          But here in the nation’s political capital, Tan is far less known. He’s hoping to grow his influence here, offering up his vast network of founders as a source of expertise for regulators struggling to wrap their heads around new technologies like artificial intelligence and how best to rein it in.

          advertisement

          “We’re happy to be a phone-a-friend for people who are trying to understand tech,” he told the Economic Club of Washington recently when asked how he’d measure success during Y Combinator’s first-ever policy-focused visit. “‘Little tech’ represents competition, and consumer choice,” he said later at a separate event in a dimly lit Senate room filled with a few dozen Congressional staffers.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          A daunting task: navigating dual Medicare, Medicaid eligibility
          A daunting task: navigating dual Medicare, Medicaid eligibility

          AdobeThreemonthsago,myauntMargarethadastroke.Daysbefore,shewasrepaintingherbathroomanddrivingherself

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

          NovoNordiskviaAPPHILADELPHIA—NovoNordisk’sobesitydrugWegovynotablycuttheriskofheartattacksinalandmar